Ignite Creation Date:
2024-05-06 @ 7:33 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06059885
Status:
RECRUITING
Last Update Posted:
2023-09-29
First Post:
2023-09-14
Brief Title:
Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC
Sponsor:
Beijing 302 Hospital
Organization:
Beijing 302 Hospital
Organization Data
Organization:
Beijing 302 Hospital
Class:
OTHER
Study ID:
ChiECRCT20210555
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Beijing 302 Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Fanping Meng
Responsible Party Title:
The Fifth Medical Centre of the General Hospital of PLA
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Beijing 302 Hospital
Old Name:
None
Old Organization:
None